Darolutamide monotherapy in patients with castration-sensitive prostate cancer (CSPC) after biochemical recurrence (BCR): ARAMON lead-in phase results.
Authors
Frank Verholen
Sepehr Nowfar
David Johnson Einstein (ORCID: https://orcid.org/0000-0001-9163-3281)
Benjamin Martin (ORCID: https://orcid.org/0009-0000-8986-1509)
Andrew Leonard Laccetti (ORCID: https://orcid.org/0000-0001-9751-8188)
Patrick Adorjan
Manjari Dissanayake
Howard I. Scher (ORCID: https://orcid.org/0000-0002-6791-9324)
Darolutamide monotherapy in patients with castration-sensitive prostate cancer (CSPC) after biochemical recurrence (BCR): ARAMON lead-in phase results.
Frank Verholen, Sepehr Nowfar, David Johnson Einstein, Benjamin Martin et al.
Citations
1 citations
Journal
Journal of Clinical Oncology
Topics
Prostate Cancer Treatment and Research
Field-Weighted Citation Impact (FWCI)
1.52
article
Darolutamide monotherapy in patients with castration-sensitive prostate cancer (CSPC) after biochemical recurrence (BCR): ARAMON lead-in phase results.
Frank Verholen, Sepehr Nowfar, David Johnson Einstein, Benjamin Martin, Andrew Leonard Laccetti, Patrick Adorjan, Manjari Dissanayake, Howard I. Scher, Xin Gao, Matthew R. Smith
article en
1 citations
Abstract
No abstract available for this paper.
Publication Tag
Journal of Clinical OncologyVol. 43(5_suppl)
Institutions
Beth Israel Deaconess Medical Center (US), Memorial Sloan Kettering Cancer Center (US), Harvard University (US), Bayer (United States) (US), Genesis HealthCare (US), Massachusetts General Hospital (US), Genesis Healthcare (US), Bayer (Switzerland) (CH)